In summary, the tumor regressions and pathological responses achieved with navitoclax + EGFR-targeted ADCs, together with the finding that the majority of TNBCs co-express EGFR and BCL-2/XL underscore the significant potential of navitoclax to enhance the effectiveness of EGFR-targeting ADCs and highlight navitoclax+ABBV-321 as a treatment option for therapy-resistant advanced/metastatic TNBCs that express high levels of EGFR. This evidence concerns the gene EGFR and neoplasm.